Pfizer acquires Seagen

Pfizer agreed to acquire Seagen. Reported deal value: Undisclosed. Status: Pending. Sector: Pharmaceuticals. Target headquarters context: Location not specified.

This page summarizes publicly available information about the transaction as of 2026-02-06. Figures and status may change as filings and press coverage update.

Does Pfizer outbidding of Merck in the acquisition of Seagen consolidate gains for patients given the up and down history of the antibody drug conjugate field and funnel new oxygen into novel applications? Or does this merger winnow down alternatives and close commercial paths for otherwise promising but currently overlooked ADC entities? The history of gemtuzumab ozogamicin—first approved in 2000, removed from most markets in 2010 , then reapproved by FDA and the European Medicines Agency in 2017 —underscores the bifurcated belief in the ADC approach itself